Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT05241873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05241873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1
Overall status
Terminated
Start date
March 4, 2022
Completion date
July 31, 2024
Enrollment
103 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, antineoplastic agents, brain metastases, bronchial neoplasms, carcinoma, carcinoma, bronchogenic, carcinoma, non-small-cell lung, egfr activating mutation, egfr atypical mutations, including g719x and l861q, egfr exon 20 insertion mutation, egfr exon 20 mutation, egfr-mutated nsclc, lung diseases, lung neoplasm malignant, metastatic lung cancer, neoplasms, neoplasms by histologic type, neoplasms by site, respiratory tract disease, respiratory tract neoplasms